In a transgenic mouse model of ALS, treatment with IL-33 delayed disease onset in female mice and reduced the proportion of CD4+ and CD8+ T cell populations in the spleen and lymph nodes. Here, IL33 is linked to amyotrophic lateral sclerosis.